Two-year experience with FK 506 in pediatric patients.

The starting dose of FK 506 has been kept the same in the pediatric population as when the drug was introduced: 0.15 mglkgld IV as a continuous infusion and 0.15 mglkg bid orally. 1 The dose was increased in case of rejection if the trough serum FK 506 level was <2 ng/mL and there was no nephrotoxicity. The dose was decreased in the absence of rejection if the serum FK 506 level was > 3 ng/mL or if there was nephrotoxicity. The doses. including starting dose. were lower in the presence of liver dysfunction. as in liver rescue attempts.